Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 20.
doi: 10.1097/INF.0000000000005059. Online ahead of print.

Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5

Ester Parada-Ricart  1   2   3 , Núria Lledó-Gras  1   2 , David Aragonès-Zabalza  1   2 , Carmen Paima-Miguel  1 , Ana Aparisi-Esteve  1 , Marina Rodriguez-Hidalgo  1 , Gabriel Zarauza-Pellejero  1 , Xavier Viñas-Fernández  1 , Maria Del Mar Albújar-Font  1   2
Affiliations

Impact of Nirsevimab in Its Second Season on Respiratory Syncytial Virus and Non-RSV Admissions in Children Under 5

Ester Parada-Ricart et al. Pediatr Infect Dis J. .

Abstract

Background: Nirsevimab was incorporated into the universal infant immunization schedule in October 2023. While its effectiveness during the first season has been described, real-world data on the second season and its impact on other respiratory virus hospitalizations are still limited, though more studies are likely to forthcoming. We aimed to evaluate the effect of nirsevimab implementation on hospital and PICU admissions for acute lower respiratory tract infections, including respiratory syncytial virus (RSV) and non-RSV etiologies, in children under 5 years of age with a specific focus on the second postintroduction season.

Methods: This retrospective study was conducted at a tertiary center in Tarragona, Spain. We included children under 5 hospitalized with acute lower respiratory tract infections (ALRTI) during the RSV seasons between 2018 and 2025 (excluding the 2020-2021 season due to the coronavirus disease pandemic). Demographic data, length of hospital stay, pediatric intensive care unit [PICU] stay and need for ventilatory support, were analyzed.

Results: Among 1384 ALRTI hospitalizations, 661were RSV-confirmed and 375 required PICU admission. After nirsevimab rollout, hospital admissions due to RSV decreased from 5.04 to 2.5 per 1000 (P < 0.001), hospitalizations due to non-RSV decreased from 5.1 to 3.54 per 1000 children <5 years (P = 0.004) and PICU admissions due to ALRTI (RSV and non-RSV) declined from 2.9 to 1.3 per 1000 children (P < 0.001). No differences were observed between the first and second postimplementation seasons in hospitalization, need for respiratory support, PICU or length of stay.

Conclusions: Universal nirsevimab immunization was associated with sustained reductions in RSV-related hospitalizations and critical illness, but also in hospitalizations due to other respiratory viruses.

Keywords: hospitalization; immunization; nirsevimab; public health; respiratory syncytial viruses; respiratory tract infections.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

References

    1. Li Y, Wang X, Blau DM, et al.; Respiratory Virus Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–2064.
    1. Palmas G, Trapani S, Agosti M, et al.; Associazione Ospedali Pediatrici Italiani (AOPI) Network. Disrupted seasonality of respiratory viruses: retrospective analysis of pediatric hospitalizations in Italy from 2019 to 2023. J Pediatr. 2024;268:113932.
    1. Ye S, Deng S, Miao Y, et al. Understanding the local-level variations in seasonality of human respiratory syncytial virus infection: a systematic analysis. BMC Med. 2025;23:55.
    1. Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7:180–189.
    1. Moline HL, Tannis A, Toepfer AP, et al.; New Vaccine Surveillance Network Product Effectiveness Collaborators. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus–associated hospitalization among infants entering their first respiratory syncytial virus season—new vaccine surveillance network, October 2023–February 2024. MMWR Morb Mortal Wkly Rep. 2024;73:209–214.

LinkOut - more resources